HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Onco News
Farmaexplorer.it

Search results for "Lenalidomide"

The IDMC ( Independent Data Monitoring Committee ) found a statistically significant improvement in time to disease progression in patients with multiple myeloma receiving Lenalidomide ( Revlimid ) pl ...


Initial clinical results from Pivotal Phase III Special Protocol Assessment ( SPA ) trials using Revlimid ( Lenalidomide ) as a new approach in the treatment of heavily pretreated patients with relaps ...


A multicenter Phase II trial, MDS-002, showed that Revlimid ( Lenalidomide ) is active in a larger group of patients with low and intermediate-1 risk myelodysplastic syndromes ( MDS ), who lack a dist ...


Researchers at the Mayo Clinic Cancer Center demonstrated that combination therapy with Lenalidomide ( Revlimid ) and Dexamethasone looks like a breakthrough treatment for multiple myeloma. The combi ...


Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, has shown that the use of a low dose of the steroid Dexamethasone ( Decadron ), in combi ...


Lenalidomide ( Revlimid ) is safe and well-tolerated for elderly patients with chronic lymphocytic leukaemia ( CLL ), a group without a well-defined frontline therapy for their disease, researchers fr ...


Lenalidomide ( Revlimid ) is safe and well-tolerated for elderly patients with chronic lymphocytic leukaemia ( CLL ), a group without a well-defined frontline therapy for their disease, researchers fr ...


High-dose Dexamethasone is a mainstay of therapy for multiple myeloma. However, a study published in the Lancet Oncology concludes that Lenalidomide ( Revlimid ) plus low-dose Dexamethasone is associa ...


A new three-drug combination has shown in a phase 1/2 clinical trial that it is a highly effective regimen in the treatment of patients newly diagnosed with multiple myeloma.Partial responses or bette ...


Results from a study published in Blood, the Journal of the American Society of Hematology ( ASH ), have demonstrated that inclusion of Carfilzomib ( Kyprolis ), a novel targeted therapy for multiple ...


For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early interv ...


The combination of lenalidomide ( Revlimid ) and Rituximab ( Rituxan ) has shown synergistic activity in chronic lymphocytic leukemia ( CLL ) preclinical models. In a CLL Research Consortium phase I ...


Carfilzomib ( Kyprolis ) is a selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In an open-label, single-arm phase 2 study ( PX-171-003- ...


Lenalidomide ( Revlimid ) has been linked to second primary malignancies in myeloma. Researchers have aimed to pool and analyse available data to compare the incidence of second primary malignancies i ...


Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma ( DLBCL ) given a regimen of Rituximab ( MabThera, Rituxan ), Cyclophosphamide ( Endoxan ), Doxorubicin ( Adriamycin ), Vincr ...